PD-1 and PD-1 ligands: from discovery to clinical application
Clicks: 2
ID: 295688
2007
Article Quality & Performance Metrics
Overall Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
0.0
/100
0 views
0 readers
AI Quality Assessment
Not analyzed
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
| Reference Key |
openalex_W2122639773
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Taku Okazaki, T Honjo |
| Journal | international immunology |
| Year | 2007 |
| DOI |
10.1093/intimm/dxm057
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.